Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2009 Sep 1;27(25):4109-15.

doi: 10.1200/JCO.2009.21.9527. Epub 2009 Jul 27.

Affiliations

Randomized Controlled Trial

Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial

Hanna K Sanoff et al. J Clin Oncol. 2009.

Abstract

Purpose: Racial disparities in colorectal cancer (CRC) survival are documented, but there are few data on comparative response to chemotherapy. A subgroup analysis of a multisite National Cancer Institute-sponsored trial (N9741) was performed comparing outcomes of black and white patients with metastatic CRC receiving uniform treatment.

Patients and methods: Adverse events (AEs), response rate (RR), time to progression (TTP), overall survival (OS), and dose-intensity were examined as a function of self-reported race in 1,412 patients treated with irinotecan/fluorouracil, fluorouracil/oxaliplatin, or irinotecan/oxaliplatin. Pharmacogenetic analysis was performed on 486 patients with blood available for germline DNA analysis.

Results: OS was 1.5 months shorter and TTP was 0.6 months shorter in black than white patients (OS: hazard ratio [HR] = 1.13; 95% CI, 0.90 to 1.42; TTP: HR = 0.91, 95% CI, 0.73 to 1.13); neither difference was statistically significant. RR was significantly higher in whites (41%) than blacks (28%; P = .008). Grade 3 or greater AEs were also higher in whites (48%) than blacks (34%; P = .004). These relationships were maintained in multivariate models adjusting for arm, age, sex, and performance status. There was no difference in dose-intensity of delivered therapy. Significant racial differences in prevalence of pharmacogenetic variants were observed, although small sample size precluded investigating the relationship between treatment, race, and genotype.

Conclusion: OS and TTP are similar in black and white patients treated per protocol with standardized therapy for metastatic CRC. However, RR and AEs vary considerably by race. The marked racial differences in relevant pharmacogenetics, a potential explanation for differing RR and AEs, are worthy of future study.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.

Fig 1.

Kaplan-Meier plots of time to progression (TTP) and overall (OS) survival for (A) all patients and by arm: (B) irinotecan, fluorouracil, and leucovorin; (C) oxaliplatin, fluorouracil, and leucovorin; and (D) irinotecan and oxaliplatin.

Similar articles

Cited by

References

    1. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334–357. - PubMed
    1. Doubeni CA, Field TS, Buist DS, et al. Racial differences in tumor stage and survival for colorectal cancer in an insured population. Cancer. 2007;109:612–620. - PubMed
    1. American Cancer Society. Colorectal Cancer Facts and Figures 2008-2010. Atlanta, GA: American Cancer Society; 2008.
    1. Irby K, Anderson WF, Henson DE, et al. Emerging and widening colorectal carcinoma disparities between blacks and whites in the United States (1975-2002) Cancer Epidemiol Biomarkers Prev. 2006;15:792–797. - PubMed
    1. Mayberry RM, Coates RJ, Hill HA, et al. Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst. 1995;87:1686–1693. - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources